-
Product Insights
Narcolepsy – Drugs In Development, 2023
Global Markets Direct’s, ‘Narcolepsy - Drugs In Development, 2023’, provides an overview of the Narcolepsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Narcolepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tafasitamab in Non-Hodgkin Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tafasitamab in Non-Hodgkin Lymphoma Drug Details: Tafasitamab (Monjuvi / Minjuvi)Â is a humanized monoclonal antibody. It...
-
Product Insights
Endocrine Gland Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Endocrine Gland Disorders - Drugs In Development, 2023’, provides an overview of the Endocrine Gland Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Endocrine Gland Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – GUB-014295 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GUB-014295 in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GUB-014295 in Obesity Drug Details: GUB-014295 is under development for the treatment of...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2023’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Interstitial Lung Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Fibrosis - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – GUB-002496 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GUB-002496 in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GUB-002496 in Obesity Drug Details: GUB-002496 is under development for the treatment of...
-
Sector Analysis
Artificial Intelligence in Pharma – Impact, Trends, Key Players and Top AI Drugs
This report investigates the impacts and development of Artificial Intelligence within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.